Compare · HLN vs PHH
HLN vs PHH
Side-by-side comparison of Haleon plc (HLN) and Park Ha Biological Technology Co. Ltd. (PHH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HLN and PHH operate in Package Goods/Cosmetics (Consumer Discretionary), so they compete in similar markets.
- HLN carries a market cap of $43.55B.
- Over the past year, HLN is up 1.1% and PHH is down 53.6% - HLN leads by 54.7 points.
- PHH has hit the wire 1 time in the past 4 weeks while HLN has been quiet.
- HLN has more recent analyst coverage (19 ratings vs 0 for PHH).
- Company
- Haleon plc
- Park Ha Biological Technology Co. Ltd.
- Price
- $9.80+0.87%
- $0.38-0.29%
- Market cap
- $43.55B
- -
- 1M return
- +6.18%
- -23.43%
- 1Y return
- +1.08%
- -53.60%
- Industry
- Package Goods/Cosmetics
- Package Goods/Cosmetics
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- 2024
- News (4w)
- 0
- 1
- Recent ratings
- 19
- 0
Haleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom. Haleon plc(LSE:HLN) operates independently of GSK plc as of July 18, 2022.
Latest HLN
- SEC Form 6-K filed by Haleon plc
- SEC Form 6-K filed by Haleon plc
- Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
- SEC Form 6-K filed by Haleon plc
- One in Three Western Consumers Now Buy Products Discovered on Social Platforms as AI Reshapes Commerce, According to NIQ
- SEC Form 6-K filed by Haleon plc
- SEC Form 6-K filed by Haleon plc
- Advil Challenges Sports Culture's "No Pain No Gain" Mentality This Summer
- SEC Form 6-K filed by Haleon plc
- Haleon Invests in India to Deliver Better Everyday Health to Rural Communities
Latest PHH
- Park Ha Biological Technology Co., Ltd. Announces Official Approval of Its North American Amazon Store, Launching a New Era of Brand Globalization
- Park Ha Biological Technology Co., Ltd. Announces Membership Application to Personal Care Products Council (PCPC), Aligning the Brand with International Standards and Marking a Strategic Milestone in its Expansion into Amazon North America
- Park Ha Biological Technology Co., Ltd. Announces Cooperation with Amazon to Support Its Entry into the North American Personal Care Sector and Accelerate the Implementation of Its Global Strategy
- Park Ha Biological Technology Co., Ltd. announces strategic partnership with Cloud Factory Technology Holdings Limited (02512.HK) to build an AI-driven ecosystem for the beauty industry.
- Park Ha Biological Technology Co., Ltd. Announces Closing of $2.0 Million Registered Direct Offering
- Park Ha Biological Technology Co., Ltd. Announces Pricing of $2.0 Million Registered Direct Offering
- Park Ha Biological Technology Co., Ltd. announces strategic partnership with Star Plus Legend Group's wholly-owned subsidiary to build an AI-powered skincare and health ecosystem and expand its healthcare reach
- Park Ha Biological Technology Co., Ltd. Announces Closing of a US$2.45 Million Public Offering
- Park Ha Biological Technology Co., Ltd. Announces Pricing of US$2.45 Million Best-Efforts Follow-on Public Offering
- SEC Form 6-K filed by Park Ha Biological Technology Co. Ltd.